Evidence map›Paper›PMID 36104602›Full record

ArticleActa neuropathologica2022

A CHCHD6-APP axis connects amyloid and mitochondrial pathology in Alzheimer's disease.

Yutong Shang, Xiaoyan Sun, Xiaoqin Chen, Quanqiu Wang, Evan J Wang, Emiko Miller, Rong Xu, Andrew A Pieper, Xin Qi

Open access · hybridAbstract read
In one paragraph

Article in Acta neuropathologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Mitochondrial dysfunction in Alzheimer's disease: Guiding the path to targeted therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Yutong ShangDepartment of Physiology and Biophysics, Case Western Reserve University School of Medicine, 10900 Euclid Ave, E516, Cleveland, OH, 44106-4970, USA.
Xiaoyan SunDepartment of Physiology and Biophysics, Case Western Reserve University School of Medicine, 10900 Euclid Ave, E516, Cleveland, OH, 44106-4970, USA.
Xiaoqin ChenDepartment of Physiology and Biophysics, Case Western Reserve University School of Medicine, 10900 Euclid Ave, E516, Cleveland, OH, 44106-4970, USA.
Quanqiu WangCenter for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA.
Evan J WangCenter for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA.
Emiko MillerHarrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, 44106, USA.
Rong XuCenter for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA.
Andrew A PieperHarrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, 44106, USA.
Xin QiDepartment of Physiology and Biophysics, Case Western Reserve University School of Medicine, 10900 Euclid Ave, E516, Cleveland, OH, 44106-4970, USA. xxq38@case.edu.ORCID 0000-0002-9578-3890
University School · USCase Western Reserve University · USLouis Stokes Cleveland VA Medical Center · USThink A Move (United States) · US

Funding

Combine computational prediction, network analysis and genetic screening in C elegans to uncover neurodegenerative causes in Alzheimer's DiseaseR01AG061388 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI CHEN, SHU G., XU, RONG · 2018 to 2022
$3.4M
Mechanism of white matter pathology in Alzheimer's diseaseR01AG076051 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI XIN QI · 2022 to 2026
$3.0M
Role of brain lipid metabolism in Alzheimer's diseaseR01AG065240 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI QI, XIN · 2020 to 2024
$3.0M
An Integrated Reverse Engineering Approach Toward Rapid drug Re positioning for Alzheimer's DiseaseR01AG057557 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI XU, RONG · 2017 to 2021
$2.8M
Proteostasis dysregulation and alpha-synucleinR01NS115903 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI QI, XIN · 2020 to 2023
$2.4M
Rapid reverse translational drug repositioningDP2HD084068 · NICHD · CASE WESTERN RESERVE UNIVERSITY · PI XU, RONG · 2014 to 2014
$2.4M
Collision of Alzheimers disease and COVID-19 pandemic in the United States: risks, outcomes, disparities and treatmentsRF1AG076649 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B, XU, RONG · 2022 to 2022
$2.3M
Regulation of CHCHD6 in Alzheimer's diseaseRF1AG074346 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI QI, XIN · 2022 to 2022
$2.1M
Construct large-scale phenomes of disease and drugs and develop data-driven systems approaches to understand genetic links between Alzheimer's disease and Neuropsychiatric symptomsR56AG062272 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI XU, RONG · 2018 to 2019
$1.6M
Collision of Alzheimers disease and COVID-19 pandemic in the United States: risks, outcomes, disparities and treatmentsR01AG076649 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI Rong Xu · 2025 to 2026
$1.6M
NIA NIH HHS R01 AG057557NIA NIH HHS R01 AG061388NIA NIH HHS R01 AG065240NIA NIH HHS R01 AG076051NIA NIH HHS R01 AG076649NIA NIH HHS R56 AG062272NIA NIH HHS RF1 AG074346NIA NIH HHS RF1 AG076649NICHD NIH HHS DP2 HD084068NINDS NIH HHS R01 NS115903
6 · The paper itself

Abstract

The mechanistic relationship between amyloid-beta precursor protein (APP) processing and mitochondrial dysfunction in Alzheimer's disease (AD) has long eluded the field. Here, we report that coiled-coil-helix-coiled-coil-helix domain containing 6 (CHCHD6), a core protein of the mammalian mitochondrial contact site and cristae organizing system, mechanistically connects these AD features through a circular feedback loop that lowers CHCHD6 and raises APP processing. In cellular and animal AD models and human AD brains, the APP intracellular domain fragment inhibits CHCHD6 transcription by binding its promoter. CHCHD6 and APP bind and stabilize one another. Reduced CHCHD6 enhances APP accumulation on mitochondria-associated ER membranes and accelerates APP processing, and induces mitochondrial dysfunction and neuronal cholesterol accumulation, promoting amyloid pathology. Compensation for CHCHD6 loss in an AD mouse model reduces AD-associated neuropathology and cognitive impairment. Thus, CHCHD6 connects APP processing and mitochondrial dysfunction in AD. This provides a potential new therapeutic target for patients.

Indexed as

Alzheimer DiseaseAmyloidosisAmyloidAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsDisease Models, AnimalHumansMammalsMiceMice, TransgenicMitochondriaMitochondrial MembranesMitochondrial ProteinsAmyloidAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAPP protein, humanAPP protein, mouseCHCHD6 protein, humanMitochondrial ProteinsAlzheimer’s diseaseAmyloid-beta precursor proteinCHCHD6MitochondriaNeurodegenerationNeuroprotection

Identifiers

PMID36104602
PMCPMC9547808
OpenAlexW4295786567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.